Chapter 14: Cancer in Children and Adolescents

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

80%.

By the time a child is diagnosed with cancer, 80 % of the time, the disease has already spread to distant sites in their body.

Right.

It's already metastasized.

Exactly.

It's already metastasized.

And I mean, if you were looking at an adult patient,

an 80 % metastasis rate at diagnosis would point to just a catastrophic failure of medical screening.

Oh, absolutely.

It would mean we missed the early warning signs for years.

But in children, it's not a failure of screening.

It's a massive blaring clue that we are dealing with a completely different biological mechanism.

It is a phenomenal point to start on.

That single statistic really just, it completely shatters the lens through which most people view oncology.

Because when you are standing at the bedside as a health science professional, you simply cannot apply the rules of adult pathophysiology to a pediatric patient.

You just can't.

No, because a child is not just a miniature adult.

Their biology is actively constructing And when that construction process goes awry, the resulting disease behaves with just astonishing speed and aggression.

OK, let's unpack this.

Today, we are taking a deep dive into Chapter 14,

Cancer in Children and Adolescents, from your text, Pathophysiology, the Biologic Basis for Disease in Adults and Children.

Yes.

Our mission today is to provide you, the nursing or health science student tuning in right now, with a personalized one -on -one tutoring session.

And advanced pathophysiology can often feel like standing at the bottom of a mountain looking up at just an absolute avalanche of cellular pathways and mutated genes.

It really does.

It feels completely overwhelming.

It does.

But today, you can take a deep breath.

We're going to master this single crucial topic together, deeply and comprehensively.

We are.

And we're going to take our time, right?

We're going to build this logically from the ground up.

Exactly.

You do not need to rote memorize a textbook today.

Instead, you need to understand the fundamental logic of the disease process.

Right.

We'll look at the statistical landscape to see who this affects.

Then we're going to explore the unique tissue origins, the embryonic layers where these cancers are actually born.

And from there, we'll deconstruct the specific types of pediatric malignancies, unpack the incredibly complex dance between genetic mutations and environmental triggers, and finally, look at the lifelong realities of survivorship.

Yeah.

Because the normal physiology of human growth directly dictates the altered cellular function, which in turn explains the exact clinical signs you will be managing in your patients.

So let's start with the big picture, the statistical landscape.

And right away, the data presents us with a really striking paradox.

Childhood cancer is rare.

It is genuinely statistically rare.

Right.

Yet the text points out that it remains the leading cause of death resulting from disease in children and adolescents.

Wait, let me stop you there.

If childhood cancer is so rare, why does it feel like we hear about pediatric leukemia or brain tumors so often?

What am I missing?

Well, you're recognizing the profound weight of pediatric mortality.

It feels common because the impact is so devastating and because structurally, we've dedicated massive pediatric wards to treating it.

Right.

That makes sense.

But the numbers tell the true story of its rarity.

For the year 2020, it was anticipated that a little over 16 ,500 children and adolescents, meaning those 19 years of age and younger, would be diagnosed with cancer in the U .S.

Wow.

Okay.

Yeah.

That gives us an overall incidence rate of 18 .7 per 100 ,000.

Now, contrast the pediatric mortality rate with the adult mortality rate.

Between 2013 and 2017, the cancer -related death rate for children and adolescents was 2 .5 per 100 ,000 for males and 2 .0 for 100 ,000 for females.

Okay.

So very low.

Right.

Compare that to the adult cancer -related mortality rate in 2017, which was 183 .9 per 100 ,000.

Oh, wow.

That is a massive difference.

The adult burden is astronomically larger.

But because children do not typically die from heart disease, COPD, or stroke, cancer becomes the apex disease threat of childhood.

That makes perfect sense.

The denominator, the total number of childhood deaths from all causes, is so much smaller, which amplifies the presence of cancer.

Precisely.

But alongside that heavy reality is an incredible testament to medical science.

The text highlights that back in the 1960s, the five -year survival rate for children and adolescents with cancer was hovering around 59 percent.

Barely over half.

Right.

Today, that survival rate has rocketed to nearly 85 percent.

When you're studying for your boards, you need to understand what drove that massive leap.

It wasn't one single miracle drug, was it?

No, not at all.

That 85 percent survival rate is the hard -won result of decades of grueling, systematic clinical coordination.

It's the result of shifting away from single -agent treatments to aggressive combination chemotherapy.

It's the implementation of multimodal treatment strategies where surgery, radiation, and chemotherapy are orchestrated perfectly for solid tumors.

Like a coordinated attack.

Exactly.

It includes incredible modern advances in targeted therapies, and most crucially, widespread participation in multi -site clinical trials.

Unlike adult oncology, where trial participation is often quite low, the vast majority of pediatric patients are treated on collaborative clinical protocols.

That coordination is exactly what has saved those lives.

I want to look closer at exactly who is getting sick.

The raw data on demographics shows that this disease does not strike evenly across a lifespan.

No, it doesn't.

We see a very specific bimodal age distribution.

That means if you chart out the incidence of childhood cancer, you see two massive peaks.

The first peak hits early in children under five years of age.

Then the incidence drops, only to spike again in a second peak during adolescence between 15 and 19 years of age.

And we also see distinct variations in gender and race that you must consider during clinical assessments.

Right, like what?

Well, overall, childhood cancer is slightly more common in boys than in girls, presenting a male to female ratio of 1 .2 to 1 .0.

When analyzing racial and ethnic groups, the overall incidence is higher in white children compared to other groups.

But you cannot stop at the top line summary.

You really have to look at specific disease variations.

Right, the breakdown.

For example, if we look at acute lymphocytic leukemia, or AL, the overall incidence is 1 .6 times greater among white children than it is among black children.

However, if we out and look at the incidence of leukemia as a whole category, the highest overall incidence is actually found among Hispanic children.

Wow.

Yeah, these demographic nuances are absolutely critical when you, as a clinician, are evaluating risk profiles in diverse, real -world patient populations.

So we know the who and the when, but to truly master advanced pathophysiology, we have to understand the where and the why.

Right.

The origin.

This brings us to the tissue of origin.

This is the absolute core of why pediatric cancer behaves so radically differently from adult cancer.

To understand it, I want you to imagine the developing adolescent body, or even earlier, the growing embryo.

Yes, think back to developmental biology.

The text walks us through the mesodermal germ layer.

Instead of looking at a static diagram, imagine you are looking at a cross -section of an early embryo inside the uterus.

From the outside in.

Then you have the maternal blood pool supplying the life force, the endometrium, the chorion, the amnion, the amniotic cavity filled with fluid, and deep inside, the yolk sac lined with endoderm along with the alantois.

And nestled within that developing structure are three primary embryonic germ layers.

Yeah, the blueprints.

Exactly.

These three layers are the foundational blueprints that will eventually differentiate to form every single organ and tissue in the human body.

You have the endoderm, the ectoderm, and the mesoderm.

So what do they each do?

Well, the endoderm goes on to become the inner linings of the body, the respiratory tract, the digestive system, the liver, and the pancreas.

The ectoderm forms the outer and sensory structures, the skin, the hair, the nails, and the central nervous system.

And the last one?

The crucial layer, the absolute epicenter for our discussion of pediatric oncology, is that middle layer.

The mesoderm.

Right, the mesoderm layer is the structural workhorse.

It develops into the body's connective tissue, bone, cartilage, muscle, blood vessels, the gonads, the kidneys, and the entire lymphatic system.

Yes.

And here is the key takeaway.

The vast majority of childhood cancers originate right there in the mesodermal germ layer.

That is the pivotal pathophysiological distinction.

To grasp this, you must contrast it with adult oncology.

Because adults are different.

Entirely.

The overwhelming majority of adult cancers are carcinomas.

Carcinomas arise from epithelial tissue, which is derived from the endoderm and ectoderm.

Why do adults get carcinomas?

Because those epithelial tissues, the lining of your lungs, the mucosa of your colon, the surface of your skin, are the body's armor.

They face the outside world.

Over decades, they are relentlessly bombarded by environmental carcinogens.

Smoking, ultraviolet radiation, dietary toxins, industrial chemicals.

Just constant wear and tear.

Exactly.

It takes years, often decades, of repeated cellular trauma and accumulated genetic mutations for a carcinoma to develop.

But a two -year -old child hasn't lived long enough to accumulate 50 years of environmental damage.

Their cancer is not a disease of outward environmental exposure.

Instead, their cancers arise from the mesoderm, the very tissues that are actively aggressively dividing to build the structural and hematologic framework of their growing bodies.

Yeah.

And that's why they behave so differently.

I always like to think of adult cancer like a car that has been driven in the bitter snow, the rain, and the sleep for 50 years.

Eventually, all that environmental wear and tear causes rust to form on the surface, on the exterior paneling.

That's a great way to put it.

That rust is exactly like an adult carcinoma.

It's the physical manifestation of long -term environmental exposure.

But pediatric cancer is an entirely different mechanism.

Completely different.

Tebiatric cancer is like a massive glitch happening directly on the factory assembly line while the car's internal engine is actively being bolted together.

It is a developmental embryological error occurring in the mesoderm while those connective tissues and blood cells are rapidly dividing to build the child's body.

That analogy perfectly captures the biology.

And because these tumors originate from early developmental mesodermal tissues during peak periods of highly orchestrated physical growth,

their cellular nature dictates that they are incredibly fast growing.

Which explains the latency period.

Yes.

The latency period is the time elapsed from the initial cellular error, the glitch on the assembly line, to the actual onset of clinical symptoms.

And in adults, that can be a long time.

Decades, usually.

But in children, the latency period is remarkably short.

Furthermore, because these early cells are often intrinsically designed to be mobile, like developing blood and lymphatic cells, pediatric cancers spread with terrifying speed.

Wow.

Which brings us full circle to your opening thought.

This is exactly why 80 % of childhood cancers have already metastasized or spread to distant sites by the time a diagnosis is made.

It is a devastating reality, but understanding that mesodermal factory glitch origin completely reorients how we view the disease.

It really does.

So we know these glitches happen, and we know they peak at specific developmental ages.

But what do these glitches actually look like?

If we walk onto a pediatric oncology floor, what exactly are we treating?

Well, let's look at the distribution of these specific cancers, and we will see how heavily it depends on the age of the patient.

If you look at the raw data of who gets sick, you see two completely different landscapes based on those bimodal peaks we discussed earlier.

Let's look at children between the ages of 0 and 14.

The younger demographic.

Right.

In this younger demographic, leukemia completely dominates the clinical picture.

It accounts for 26 % of all cancer cases.

Over a quarter.

Yes.

Specifically, we are looking primarily at acute lymphocytic leukemia, or OL, following very closely behind leukemia are brain and central nervous system tumors, which make up 21 % of cases.

So right out of the gate, nearly half of all childhood cancers are either in the blood or in the brain.

After those top two, the percentages get smaller, but the diseases are no less severe.

You see neuroblastoma coming in at 7%, which includes conditions like ganglion neuroblastoma.

Right.

Then you have non -Hodgkin lymphoma at 6%, Wilms tumor, a cancer of the kidneys at 5%, acute myeloid leukemia or AML at 5%, and bone tumors, which include osteosarcoma and Ewing sarcoma sitting at 4%.

And you also see smaller percentages of Hodgkin lymphoma, rhabdomyosarcoma, and retinoblastoma.

But then the text asks us to shift our focus to the adolescents, the 15 to 19 -year -olds.

And when you look at that demographic, the entire landscape just shifts beneath our feet.

It does, and it shifts because the biology of the patient is fundamentally transforming during puberty.

Right.

In the adolescent group, Hodgkin lymphoma suddenly leaps to the forefront, accounting for 15 % of all cases.

Thyroid carcinoma surges to 11%.

Brain and CNS tumors remain highly significant at 10%.

Now we see some new ones appear, right?

Yes.

We also see testicular germ cell tumors appearing at 8 % and non -Hodgkin lymphoma at 8%.

What's really revealing is that we begin to see melanomas accounting for 6 % and ovarian germ cell tumors at 2%.

Exactly.

What you are witnessing in this older age bracket is the biological bridge between childhood and adulthood.

As adolescents age, the incidence of carcinomas, those cancers originating from the epithelial tissue, begins to steadily increase as environmental exposures begin to accumulate.

Let's break down some of these major players a bit more, starting with the titan of pediatric oncology, leukemia.

As you said, it is the most common malignancy in children.

It is.

The absolute peak incidence for leukemia occurs when a child is between 2 and 5 years of age.

We mentioned ALL -L, acute lymphocytic leukemia, which represents about 75 % of all childhood leukemia cases and nearly half of all adolescent cases.

But here's something I want to clarify for the clinicians standing at the bedside.

The text notes that the presenting signs of the various types of leukemia like ALL -L versus AML might look virtually identical when a patient walks into the clinic.

They often do.

A child might present with profound pallor, unexplainable fatigue, or sudden severe bruising, but what is happening inside the bone marrow is vastly different, right?

Exactly.

The outward clinical manifestations, pallor from anemia, bruising from thrombocytopenia, infections from neutropenia, are the result of the bone marrow failing because it is packed with malignant cells.

It's just overcrowded.

Yes.

But the treatment protocols, the chemotherapeutic agents used, and the patient's biological response to those treatments vary wildly depending on whether those malignant cells are lymphocytic or myelogenous in origin.

So you really need to know what you're fighting.

You cannot simply treat quote unquote leukemia.

You must treat the highly specific cellular lineage that has gone rogue.

Moving from the blood to solid tumors, we hit central nervous system, or CNS, tumors.

These are the most common solid tumors in children, accounting for 26 % of childhood cancers and 20 % of adolescent cancers.

Right.

And again, we see a peak incidence in children under 15 years of age.

But reading the text, the clinical reality of treating these tumors is just heartbreaking.

When an adult has a brain tumor, we utilize surgery, chemotherapy,

and aggressively target it with radiation.

But we cannot just seamlessly apply that to a toddler.

No, we cannot.

And the pathophysiology of the developing brain simply forbids it.

Why is that?

Treating brain tumors in children is exceptionally complex and fraught with long -term risk.

The therapies we heavily rely on, particularly cranial radiation therapy,

can have devastating permanent effects on a rapidly developing neural network.

Because their brains are still growing.

Exactly.

This is especially true for children younger than three years of age.

Their brains are still undergoing massive foundational neurodevelopment and myelination.

Irradiating that tissue can lead to profound, irreversible cognitive and developmental deficits.

That is such a heavy burden for the care team.

It is.

Furthermore, you must understand a critical distinction regarding the word benign.

If a tumor in the breast or the arm is histologically classified as benign, it means the cells are not malignant.

They are not invading local tissue.

But in the central nervous system, histology is only half the story.

Because there's no room in the skull.

Right.

Anatomy dictates survival.

A histologically benign tumor can have catastrophic or even fatal effects simply based on its location inside the rigid, unyielding structure of the human skull.

Oh, wow.

A benign mass growing on the brainstem and compressing vital respiratory centers is an immediate life -threatening emergency, regardless of how the cells look under a microscope.

That distinction between how a cell looks under a microscope and what it is physically doing to the brain anatomy is such a vital concept to grasp.

It's crucial.

Next, we look at lymphoma, comprising both Hodgkin and non -Hodgkin types.

This ranks as the third most common type of childhood cancer, but its timeline is unique.

Very unique.

Lymphoma is incredibly rare in young children under five years old.

It only becomes highly prevalent as children reach 10 years of age and transition into adolescence.

Then we have a category that sounds like it belongs purely in a developmental biology class.

Embryonal tumors.

The text explains that these tumors actually begin their pathogenesis during intralodarin life.

Yes, these are fascinating from a pathophysiological standpoint.

Embryonal tumors consist of abnormal cells that essentially look and behave like immature embryonic tissue.

So they don't grow up.

Right.

Normal embryonic cells differentiate.

They mature into specialized cells with specific jobs.

But embryonal tumor cells lack the ability to mature.

They just stay stuck.

They are locked in a primitive state, dividing rapidly without ever differentiating into functional tissue.

Because this error originates so incredibly early in human development, often while the fetus is still in the womb, these cancers are almost always diagnosed very early in life, usually before the child reaches five years of age.

When you are looking at medical terminology, there is a very consistent clue.

The names of these embryonal tumors often include the root word blast.

Yes, that's a great tip.

That suffix blast literally indicates that the cells are stuck in an immature embryonic stage of development.

So when you are looking at a chart and you see neuroblastoma, a tumor of the sympathetic nervous system, or retinoblastoma, a tumor of the eye, you immediately know you are dealing with an embryonal tumor.

Exactly.

You know those cells are frozen in an immature state, and the disease process likely began before the child was even born.

Precisely.

Finally, we must look at the sarcomas.

Sarcomas arise from connective tissues.

Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood.

And it has its own bimodal curve, right?

It does.

It presents with a fascinating bimodal age distribution of its own.

Two -thirds of rhabdomyosarcoma cases occur in young children under six years of age, while the remaining one -third occur in children and adolescents ten years of age and older.

And then the bone tumors.

Right.

Then we have the primary bone tumors, which are osteosarcoma and Ewing's sarcoma.

If you look at the incidence data, these bone and joint cancers are far more likely to occur in adolescents who are 15 years of age or older.

Because they're growing so fast.

What's fascinating here is how perfectly the incidence of these specific cancers tracks with the body's natural physiological growth and maturation phases.

It really is.

Think about what is happening to a 15 -year -old.

They are going through massive, rapid skeletal growth spurts.

The underlying cellular regulatory mechanisms that drive that normal, healthy bone growth are the exact same pathways that, when slightly altered or genetically dysregulated, lead to osteosarcoma.

So the cancer is essentially hijacking the adolescent growth spurt.

Exactly.

That intrinsic connection between normal development and abnormal pathology is what creates that distinct bimodal incidence curve.

It is a dark kind of brilliance how the disease mirrors human development.

The cancer just uses the body's own momentum against it.

It's devastating, but logically it's exactly what's happening.

So we know these mesodermal glitches happen and we know they peak at specific ages, but the multi -million dollar question that the parents are going to ask you when you are standing in the hospital room is, why?

What actually broke the machinery in my child's cells?

The hardest question.

This brings us to etiology, the origin of the disease.

Specifically, the complex multifactorial model and the genomic factors.

When a devastated family asks you why their child got cancer,

the hardest, truest clinical answer you can give is that, in the vast majority of cases,

the specific causes remain largely unknown.

Right.

However,

scientifically, we utilize a multiple causation model, which is also known as multifactorial etiology.

So multiple factors working together.

Yes.

This model states that cancer does not happen in a vacuum.

It develops due to an incredibly complex, poorly understood interaction between the predisposing characteristics of the host, meaning the child's unique biological and genetic makeup, and external environmental factors.

And this multifactorial reality completely changes how we view early warning signs.

Think back to our earlier discussion about the short latency period and the fast -growing mesodermal tissues.

Because pediatric cancers explode onto the scene so rapidly, the early warning signs we rely on for adults are virtually useless for kids.

Completely useless.

The American Cancer Society's famous seven warning signs for cancer, things like a change in bowel habits, a lingering cough, indigestion, those describe the gradual, creeping manifestations of environmentally caused carcinomas.

They simply do not apply to a rapidly expanding embryonal tumor that has taken over a two -year -old's abdomen in a matter of weeks.

Early population -based screening strategies like mammograms or colonoscopies for adults just have not proven effective for most childhood cancers.

Except in very specific cases where a child has a known documented genetic mutation or a strong family history.

Which means we must shift our focus away from outward screening and look inward at the genetics at the cellular level.

The DNA.

Acquired or inherited mutations in individual genes are the primary drivers of these cellular glitches.

So understand this, you must understand three main categories of genes.

Proto -oncogenes, tumor suppressor genes, and Mismax repair genes.

Okay, let's break this down.

Let's start with proto -oncogenes.

In a healthy, functioning cell, proto -oncogenes are essential.

They code for proteins that carefully regulate normal cell growth, division, and differentiation.

They are heavily involved in the pathways that tell a cell when it is time to multiply.

So they're the good guys.

Normally, yes.

However, if a proto -oncogene sustains a mutation, it becomes an oncogene.

An oncogene acts like a jam signal.

It dysregulates the cell cycle, constantly instructing the cell to divide unchecked.

It just won't stop.

Exactly.

Essentially helping turn a normal cell into a cancer cell.

An excellent, heavily tested example of an oncogene identified in pediatric oncology is the MYCN gene.

MYCN.

Yes.

When MYCN goes rogue, it is deeply involved in the development and aggressive progression of neuroblastoma and glioblastoma.

Okay, I want to bring back our car analogy to make this crystal clear.

If proto -oncogenes are the gas pedal of the cell, carefully pushed only when the car needs to move forward, an oncogene is what happens when someone super glues the gas pedal to the floor.

That's a perfect visual.

The car is going to accelerate wildly out of control.

But a car with a stepped gas pedal can still be stopped if the brakes work.

That brings us to the second category.

Tumor suppressor genes.

These are the brakes.

Right.

They are protective genes that are supposed to recognize abnormal cell growth and suppress cancer cell proliferation.

But if they mutate and lose their suppressor function, the brakes fail.

And there is a crucial genetic rule here.

A child inherits two copies of every gene, one from each parent.

For a tumor suppressor gene to completely fail, both copies, both alleles, must acquire mutations.

So both brakes have to be cut.

Exactly.

If only one brake line is cut, the car can still stop.

But if both are cut, you lose all normal function and cancer can develop unchecked.

When those tumor suppressor genes fail, we see childhood cancers like leukemia, osteosarcoma,

rhabdomyosarcoma, retinoblastoma, and Wilms tumor.

And to complete the analogy, we have to look at the mechanic whose job is to keep the car functioning.

The mismatch repair genes.

The proofreader.

Right.

Every time a single cell divides, it has to copy billions of base pairs of DNA.

Naturally, spelling errors occur in that sequence.

Mismatch repair genes act like molecular proofreaders or mechanics.

They constantly scan the newly synthesized DNA, recognize the errors, and fix them.

They also repair DNA damage caused by internal cellular stress.

But what happens if the mechanic is asleep on the job?

The errors just build up.

Yes.

If there are mutations in both alleles of a mismatch repair gene, the cell loses its ability to fix its own DNA.

The mutations begin to pile up exponentially.

In pediatrics, this leads to a distinct and incredibly severe phenotype known as Constitutional Mismatch Repair Deficiency Syndrome, or CMMMRD.

CMMMRD.

Yes.

A child affected by CMMMRD is a highly penetrating cancer predisposition syndrome.

Their cells simply cannot fix daily DNA damage, leading them to develop exceptionally aggressive cancers, including devastating lymphomas, leukemias, and sarcomas, often very early in life.

Here's where it gets really interesting.

We aren't just talking about abstract genetic concepts.

These mutated genes manifest as very specific, recognizable clinical syndromes in your patients.

They absolutely do.

Let's dive deep into the specific congenital factors and syndromes associated with childhood cancer.

As a nursing student, you will absolutely encounter patients with these underlying conditions.

Let's start with single -gene autosomal recessive conditions.

Autosomal recessive means the child had to inherit a mutated copy of the gene from both the mother and the father.

Fanconi anemia is a prime example.

Fanconi anemia results in fundamentally altered DNA repair mechanisms.

And that leads to major risks.

Huge risks.

Individuals with this condition have an extremely high risk of developing acute myelogenous leukemia, or AML, as well as myelodysplastic syndrome and hepatic, or liver, tumors.

Another autosomal recessive condition is Bloom syndrome.

Bloom syndrome causes extreme chromosomal fragility.

The chromosomes just break.

Literally, yes.

The chromosomes physically break and rearrange far more easily than normal, leading to increased mutations across the board.

Children born with Bloom syndrome are at a heightened risk for a wide spectrum of cancers, particularly acute leukemias, lymphomas, and Wilms tumor.

Moving from recessive to dominant, we must examine autosomal dominant disorders.

In these conditions, inheriting just one mutated copy of the gene from one parent is enough to drastically increase cancer risk.

And the primary classic example in pediatric oncology is life -romany syndrome, or LFS.

LFS.

Yes.

This syndrome involves a germline mutation in the TP53 gene.

We just discussed the breaks of the cell, the tumor suppressor genes.

Well, TP53 is essentially the master tumor suppressor gene of the entire human genome.

The master break.

Exactly.

It's located on the short arm of chromosome 17.

For individuals carrying a TP53 mutation, their cellular breaking system is fundamentally compromised from birth.

The risk of developing cancer is phenomenally higher than the general population.

So what kinds of cancer are we talking about?

Children and adults in LFS families face a lifelong elevated risk for soft tissue sarcomas, breast cancer, leukemia, osteosarcoma, melanoma, and cancers of the colon, pancreas, adrenal cortex, and brain.

That is a staggering list.

It is.

Furthermore, because the underlying genetic defect is present in every cell of their body, individuals with LFS are at a remarkably high risk for developing multiple entirely separate primary cancers over the course of their lifetime.

Another vital autosomal dominant condition that you must know is retinoblastoma, that malignant embryonal tumor of the eye we mentioned earlier.

Retinoblastoma results from a genetic deletion on the long arm of chromosome 13 and what lives on the long arm of chromosome 13, the RB1 gene.

And RB1 is, you guessed it, another critical tumor suppressor gene.

Yes.

Another break.

Now, these RB1 deletions can happen in two ways.

They can be inherited germline mutations, meaning the mutation was passed down from a parent in the sperm or the egg, which causes familial retinoblastoma, or the mutations can be acquired spontaneously during early fetal development, which leads to sporadic cases of the disease.

Beyond mutations in single specific genes, we also see larger gross chromosomal abnormalities contributing to pediatric cancer.

The most prominent mechanism you need to understand is the chromosomal translocation.

A translocation?

Yes.

A translocation happens when two separate non -homologous chromosomes, meaning two chromosomes that are not a matched pair, literally break apart and physically rearrange themselves, swapping pieces of their genetic material.

They just swap parts.

Right.

When they fuse back together incorrectly, they often create what is called a fusion gene.

This is when two previously separate normal gene regions unite to create a brand new mutant set of instructions for the cell.

Okay, let me pause and make sure I'm visualizing this correctly.

It's like taking the first half of a recipe for baking a cake and taping it to the second half of a recipe for making a bomb.

Wow.

The cell reads this new fused recipe and creates a protein that it was never supposed to make.

That is an excellent, albeit terrifying, way to visualize it, and the most heavily tested classic example of this is the Philadelphia chromosome.

The Philadelphia chromosome involves a massive translocation between chromosome 9 and chromosome 22.

When these two chromosomes break and swap material, they fuse the BCR gene on chromosome 22 with the ABL gene from chromosome 9.

BCR -ABL.

Exactly.

This specific swap results in the creation of the BCR -ABL fusion protein.

BCR -ABL is an abnormal tyrosine kinase protein.

What it does in the cell is disastrous.

It actively, aggressively accelerates cell division while simultaneously inhibiting the cell's ability to repair its DNA.

Oh, that's a terrible combination.

It forces the cell to multiply rapidly while accumulating unchecked genetic damage.

The Philadelphia chromosome is a hallmark driver of chronic myelogenous leukemia and is also identified in some high -risk cases of acute lymphoblastic leukemia.

Are there other fusion genes like that?

Yes.

Another important fusion gene you will see associated with allele in children is the tele -ML1 gene, which results from similar translocation, this time between chromosomes 12 and 21.

We also see a significantly higher risk of cancer in children born with specific congenital anomalies or whole -chromosome syndromes.

The most universally recognized of these is Down syndrome, or trisomy 21, where a child is born with three copies of chromosome 21 instead of two.

Children with Down syndrome have a massively increased risk.

We're talking 10 to 20 times greater than the general population of developing both acute lymphoblastic and acute myelogenous leukemias.

They also have an even higher uniquely elevated risk of developing acute megakaryocytic leukemia.

This risk is most profound in the early years of childhood.

We also see highly specific anatomical malformations that are inextricably tied to cancer risk because they share the same genetic real estate.

Like what?

Wilm's tumor, the malignant pediatric kidney tumor, provides a prime example of this phenomenon.

In about 17 % of cases, Wilm's tumor occurs in combination with other congenital anomalies.

As a clinician, you need to recognize Waggier syndrome.

Right, Waggier is an acronym.

It stands for Wilm's tumor,

aniridia, which is the severe congenital absence of the iris, the colored part of the eye, janitorinary anomalies, which often present as ambiguous genitalia, and intellectual disability.

Why do all those seemingly unrelated things happen together?

Because Waggier syndrome is caused by a massive contiguous gene deletion on the short arm of chromosome 11.

This specific tiny region of human DNA happens to house both the WT1 gene, which is a tumor suppressor gene that prevents Wilm's tumor, and the PANCEK6 gene, which is absolutely critical for normal ocular development.

Oh wow, so they're right next to each other.

Exactly.

When that whole chunk of the chromosome is randomly deleted during fetal development, the child is born with both the kidney cancer predisposition and the severe eye defect.

Are there other syndromes linked to Wilm's tumor?

Yes.

Wilm's tumor is also strongly associated with another condition called Beckwith -Weidman syndrome.

This is a complex overgrowth disorder characterized by hemiehypertrophy, which is an abnormal asymmetrical muscular overgrowth of one half of the body or the face.

It's honestly incredible how mapping these strange physical anomalies, half a face growing larger than the other, or the absence of an iris, traces straight back to the exact physical location of a missing gene on a chromosome.

It is truly remarkable biology.

And it isn't just these named famous syndromes.

The text points out that large population -based studies show that children born with ventricular septal defects, a hole in the heart, have a ten times greater risk of developing hepatoblastoma, a rare liver cancer.

Children born with central nervous system birth defects have a 10 to 20 times increased risk of developing certain brain tumors.

It goes even further.

Even the totally healthy siblings of children with CNS, eye, or facial malformations show an increased risk of cancer compared to the siblings of completely unaffected children.

The genetic ties run incredibly deep and we are only just beginning to map them out.

And our clinical understanding of those genetic ties is expanding at lightning speed.

Yeah, let's talk about the new research.

The text includes an incredibly important discussion on cancer predisposition genes that highlights recent massive advances in genome sequencing studies.

Researchers conducted a landmark study where they sequenced the genomes of over a thousand children and adolescents diagnosed with cancer and then compared them to the genomes of healthy individuals without cancer.

And what did they find?

They found that 8 .5 % of the children and adolescents with cancer possessed a de novo germline mutation in a known cancer predisposition gene, most frequently mutations in TP53, APC, or BRCA2.

Okay, 8 .5%.

In stark contrast, only 1 .1 % of the healthy control individuals carry these mutations.

So what's the big clinical takeaway from that?

The most striking paradigm shifting finding for clinical practice.

The vast majority of the children with these cancer causing mutations had absolutely no family history of cancer.

Mutation was de novo.

It appeared spontaneously in that child's genetic code.

That completely upends how we think about familial screening.

You can't just rely on a family history questionnaire to determine if a child is genetically at risk.

You really can't.

And before we transition away from the molecular level, we have to touch on epigenetics.

It isn't always about the DNA sequence itself breaking or mutating.

Sometimes the DNA sequence is perfectly healthy, but the way the cell reads that DNA is broken.

Yes, the reading mechanism.

Think of DNA as a massive, impossibly long thread.

To fit inside the nucleus of a cell, that thread has to be tightly wound around tiny protein spools called histones.

Epigenetics looks at those schools.

Backaging.

Right.

Mutations in the genes that encode these histone proteins can cause the DNA thread to be wound too tightly or too loosely.

This physical alteration can severely decrease the expression of vital tumor suppressor genes without ever actually changing their underlying ACTG DNA sequence.

By decreasing that gene expression, you alter how a cell differentiates, which can lead directly to cancer.

These epigenetic changes are currently a massive focus of oncology research, particularly in relation to certain sarcomas and diffuse intrinsic pontine glioma, or DIPG.

DIPG is a major focus right now.

It is.

DIPG is a highly aggressive, currently incurable brain stem tumor that strikes young children, and understanding its epigenetic drivers is one of our best hopes for a future cure.

Absolutely.

Okay.

Let's take a collective breath.

We have spent a lot of time looking inward at the cellular glitches, the broken brakes, the superglued gas petals, and the mutated schools of DNA.

We have.

If genetics is the loaded gun, what environmental factors are pulling the trigger?

Unlike the adult carcinomas, where we can point clearly to decades of smoking or asbestos exposure, pediatric cancers have very few strongly established environmental links.

But the epidemiological data we do have is absolutely critical for your daily nursing practice.

Let's start with the earliest possible environment, prenatal exposures.

When we evaluate prenatal exposures, we must establish a biological baseline.

The developing fetus processes chemicals and radiation vastly differently than a mature human.

Because they're not fully formed?

Exactly.

A fetus does not have a fully mature liver to metabolize toxins, nor a developed immune system to seek out and destroy aberrant cells.

So what are some examples of transplacental exposures?

The most sobering, historically well -described example of a transplacental chemical carcinogen is a synthetic hormone drug called diethylstylbestrol, universally known as DES.

Oh yes!

Decades ago, well -meaning physicians widely prescribed DES to pregnant women under the belief that it would prevent recurrent spontaneous abortions and pregnancy complications.

But it didn't do that, did it?

No.

It wasn't until 1971 that researchers, tracking a sudden, impossible cluster of rare cancers, discovered a horrific consequence.

A small percentage of the daughters born to the women who took DPS went on to develop rare, aggressive adenocarcinomas of the vagina and cervix as teenagers and young adults.

Just awful.

The drug crossed the placenta and subtly altered the embryological development of the fetal reproductive tract.

Fortunately, since that tragedy, no other drugs taken by pregnant women have been definitively to cause cancer in their offspring, despite exhaustive, ongoing global research.

Beyond pharmaceutical drugs, we have to look at radiation and industrial chemicals.

Current epidemiological evidence suggests that there is an increased risk of childhood leukemia associated with low levels of exposure to antenatal X -rays, meaning X -rays performed on the mother's abdomen or pelvis while she is actively pregnant.

Right.

Interestingly, though, studies have not established a similar link between antenatal X -rays and the development of childhood brain tumors.

The role of pesticides in environmental toxins is also a major, fiercely debated area of study, with recent meta -analyses shedding some necessary light.

When evaluating pesticide exposure, the strongest, most consistent associations are found with maternal exposure.

Okay, what did the studies show?

Studies indicate that if a mother is exposed to significant levels of pesticides during the prenatal period, her child has a demonstrably increased risk of developing leukemia, lymphoma, and neuroblastoma.

Furthermore, maternal occupational exposure to benzene, a chemical often found in industrial solvents and manufacturing, is associated with an increased risk of all LL in the child.

Even maternal exposure to commercial hair dyes and certain occupational chemicals has shown statistically significant associations with increased risks for leukemia and neuroblastoma.

And what about paternal exposure?

We always talk about the mother's environment, but do the father's environmental exposures prior to conception, the toxins affecting his sperm, affect the child's subsequent cancer risk?

This raises an important question about preconception genetics, but the data there is much more mixed, contradictory, and less clearly defined.

It's not as clear cut.

No.

For example, some analyses from the International Childhood Cancer Cohort Consortium show that paternal exposure to pesticides was indeed associated with an increased risk of acute myelogenous leukemia in their offspring, but those same studies found no association with LAL or CNS tumors.

Conversely, a completely different study found a strong association between AL and paternal occupational pesticide exposure, while finding no link to maternal exposure.

And yet another massive comprehensive meta -analysis, looking specifically at over 1 ,400 cases of neuroblastoma, failed to find any association with paternal pesticide exposure at all.

So the science is still highly evolving and sometimes contradictory.

Very much so.

But the clinical takeaway for you is clear.

As a nurse, taking a comprehensive holistic family history, noting parental occupational exposures like either parent working extensively with agricultural pesticides, industrial chemicals, or livestock is increasingly recognized as vital data that helps build the patient's full clinical picture.

Absolutely.

So that covers the prenatal environment.

But what about exposures after the child is born and living in the world?

Let's look at childhood exposures.

We already know that high doses of ionizing radiation are firmly established, undeniable risk factors for childhood leukemia and thyroid cancers.

Right.

From atomic bombs in Chernobyl.

Yes, we learned that tragic reality from studying the survivors of the atomic bombs and the Chernobyl disaster.

But the modern, everyday clinical concern isn't a nuclear fallout, it's diagnostic imaging.

This is huge for clinical practice.

It is.

The text dedicates immense focus to the risks of CT imaging scans.

Computed tomography, or CT scans, represent only about 12 % of all diagnostic radiologic procedures performed in large hospitals.

Yet, because of the massive amount of radiation they use compared to a standard x -ray, they account for almost 49 % of the total collective medical x -ray radiation dose for the entire US population.

This is a critical, actionable area for pediatric nursing advocacy.

You are the last line of defense before that child goes into the scanner.

Epidemiologic studies clearly and unequivocally show that children are far more sensitive to radiation than adults.

Their cells are actively dividing, making their DNA more vulnerable to radiation -induced breaks.

And they have their whole lives ahead of them.

Precisely.

Because children naturally have a much longer life expectancy ahead of them, they have a massively larger window of opportunity to express any radiation -induced DNA damage as a clinical cancer decades down the line.

A recent sobering meta -analysis of over a million children found a 1 .32 -fold greater risk of subsequent cancer development among children who were exposed to CT scans compared to those who were not.

When you are standing at the bedside and the doctor orders a CT, what does this actually mean for your clinical practice?

It means you must be a fierce guardian of the Allelara Principle, as low as reasonably achievable.

LR is so important.

Children can receive a vastly higher radiation dose than is medically necessary if the CT machine's technical settings are not specifically manually adjusted for their much smaller body size.

You can't scan a 40 -pound toddler using the parameters meant for a 200 -pound adult.

You really can't.

The key nursing takeaways from the text are crystal clear.

Number one, advocate forcefully to perform only clinically necessary CT scans.

If an ultrasound or an MRI which do not use ionizing radiation can answer the clinical question, you must question the CT order.

Number two, ensure the radiological exposure parameters are rigorously adjusted for pediatric sizing.

And number three, advocate to use lower -resolution scans whenever appropriate for the specific clinical decision being made.

A perfect, high -definition image is not worth the future cancer risk if a lower -resolution image provides the exact same diagnostic answer.

That is precisely how you translate textbook pathophysiology into life -saving nursing advocacy.

Yeah, that's what it's all about.

Moving on from radiation, we must evaluate pharmacological exposures during childhood that increase cancer risk.

The text lists specific drugs that carry an alarming, well -documented risk.

Anabolic androgenic steroids, which are sometimes medically used to stimulate bone marrow growth and specific anemias or illicitly used to increase muscle mass, carry a documented risk of causing hepatocellular carcinoma and brain tumors.

And what about chemo itself?

Paradoxically and tragically, some of the very chemotherapy agents used to cure cancer can cause it.

Specifically, epipodophyllotoxins and anthracyclines are powerful chemotherapies that work by breaking cancer DNA.

But in doing so, they can damage the DNA of healthy cells enough to cause a secondary, entirely new leukemia years later.

That's just an awful double -edged sword.

It is.

Additionally, we must look at immunosuppressive agents.

These drugs are absolutely necessary to prevent the body from rejecting a newly transplanted organ.

But they suppress the immune system.

Exactly.

By pharmacologically suppressing the immune system, you also suppress the body's natural tumor surveillance mechanisms.

This significantly increases the risk of the child developing post -transplant lymphomas, because the immune cells that would normally hunt down and destroy a rogue cancer cell are medically sedated.

We also need to mention the biological environment, specifically viruses.

The strongest, most definitive association between a virus and pediatric cancer involves the Epstein -Barr virus, or EBV.

EBV infection is strongly, causally linked to the development of endemic Burkitt lymphoma, nusopharyngeal carcinoma, and Hodgkin disease.

Additionally, children living with HIV -AIDS have an exponentially increased risk of developing specific malignancies, most notably non -Hodgkin lymphoma and Kaposi sarcoma.

This is a direct result of the severe, prolonged immunosuppression caused by the HIV virus destroying the T cells.

But there is good news there.

There is.

There is a profound silver lining mentioned in the text.

The Advent and widespread global distribution of highly active antiretroviral therapy,

or of these children, drastically reducing the incidence of AIDS -related malignancies in the developed world.

While we are covering environmental exposures, it is equally important to address the exposures that have been extensively debunked or are highly misunderstood.

As a health science professional, you will inevitably have anxious parents asking you about these theories and you must respond with scientific precision.

Like cell phones and power lines.

Exactly.

The most common fear surrounds electromagnetic fields, or EMFs, the energy radiating from neighborhood power lines, household computers, and cell phones.

Parents are terrified that their child's tablet is causing a brain tumor.

Right.

How do we address that?

You must explain the difference between ionizing radiation, like x -rays, which possess enough kinetic energy to literally break chemical bombs and directly shatter DNA, and non -ionizing radiation, like EMFs.

EMFs do not have the energy required to directly damage DNA.

That's a great way to put it.

A massive task group convened by the World Health Organization exhaustively reviewed the global data.

They found that only extremely high levels of magnetic field exposure, specifically levels greater than or equal to 0 .4 microteslas, showed any weak association with an increased risk of childhood leukemia.

And how common is that exposure?

To put that technical number in perspective, less than 1 % of children worldwide are ever exposed to that level of an EMF.

So while scientific research is always ongoing, every day, standard EMF exposure from cell phones and power lines is not currently recognized as a significant causative factor for pediatric cancer.

That is exactly how you calm a parent's fear using hard science.

And speaking of unexpected science, here is a fascinating twist from the text.

Some environmental exposures might actually be protective.

Oh, the hygiene hypothesis.

Current epidemiological research suggests that early childhood exposure to common everyday infections, the standard colds and sniffles of daycare, might actually help prime a child's developing immune system.

So getting sick early can be a good thing.

Exactly.

By constantly engaging with minor pathogens, the immune system strengthens its overall surveillance capabilities,

thereby offering a protective effect against the development of acute lymphoblastic leukemia.

It is essentially the famous hygiene hypothesis, which we normally discuss regarding allergies, applied directly to pediatric oncology.

That's a really interesting point.

All right.

We have navigated the dense statistics, the embryonic origins, the cellular and genetic mechanisms and the environmental triggers.

Now we have to look forward.

What happens to the patient on the other side of this grueling diagnosis and treatment?

We have arrived at prognosis, the critical issue of the adolescent gap, and the lifelong reality of survivorship.

Let us start with the triumph of modern medicine.

As we stated at the very beginning of this session, nearly 85 % of children and adolescents diagnosed with cancer today are cured.

The absolute mortality rate plummeted from 6 .5 per 100 ,000 in 1969 to 2 .3 per 100 ,000 in 2015.

It's just a phenomenal achievement.

It is.

This staggering success is directly, undeniably attributable to the collaborative infrastructure of the Children's Oncology Group, or COG.

The COG conducts massive, highly coordinated clinical trials at more than 175 specialized pediatric hospitals across the United States.

Through relentless, meticulous iteration over decades, they have optimized combination chemotherapy protocols,

refined multimodal treatments, and drastically improved supportive care.

So what does this all mean for teenagers?

We discussed the bimodal incidence curve earlier, and we noted that cancer incidence spikes again in adolescents.

But the text highlights a deeply concerning systemic issue known as the adolescent gap.

This is a major structural problem.

It is.

Historically, adolescents and young adults have had markedly poorer outcomes and significantly lower survival rates compared to younger children with the exact same diseases.

Why?

It isn't just biology.

It is a structural failure of our medical system.

Because they get caught in the middle.

Exactly.

Adolescents exist in a messy transitional phase of life.

They are often in the process of transitioning from their childhood pediatricians to adult primary care providers.

Consequently, when a 17 -year -old develops cancer, they are frequently referred into the adult oncology system and treated at adult cancer centers rather than being routed to specialized pediatric oncology centers.

And that referral pathway, treating a teenager in an adult facility, has profound negative implications for their survival.

If an adolescent is treated in an adult facility by adult oncologists, they almost entirely miss out on access to the highly specialized collaborative pediatric clinical trials that have driven that 85 % cure rate.

And adult trials won't take them.

Right.

Furthermore, many clinical trials explicitly designed for adults have rigid age cutoffs and will not legally accept patients under the age of 18, even if the underlying cellular biology of the 17 -year -old's disease is virtually identical to the adult version.

As a result of this structural gap, adolescents have historically had abysmal rates of participation in clinical trials.

So things are changing, right?

Fortunately, yes.

The National Cancer Institute and the CAWGA recognize this crisis and are actively launching national initiatives to bridge the adolescent gap.

They are building specific trial networks for adolescents and young adults.

And thankfully, recent epidemiological data shows that their five -year survival rates are finally beginning to climb and align with those of younger children.

But as you will quickly learn in practice,

surviving the cancer is only the first major hurdle.

Pediatric cancer is no longer viewed simply as an acute, fatal illness that you either survive or you don't.

Today, because of our success in curing the primary disease,

pediatric cancer survivorship is heavily managed as a complex, lifelong chronic disease.

If we connect this to the bigger picture of your career, you as a future health science professional will be caring for these childhood cancer survivors for decades after their primary oncologist has discharged them.

You'll see them in primary care and the ER everywhere.

Exactly.

You must understand the pathophysiology of their survivorship because the life -saving treatments, the intensely cytotoxic chemotherapy, and the aggressive ionizing radiation were administered while their bodies were still physically immature and rapidly growing.

The late effects of those treatments are often severe and systemic.

What kind of late effects?

Survivors face a lifetime of managing potential physical impairments.

They face reproductive dysfunction and potential infertility due to genital radiation.

They experience soft tissue and bone atrophy, endocrine disruption, and significant learning disabilities if their developing brain required radiation therapy.

And most tragically, they face a highly elevated risk of developing secondary cancers.

We discussed this briefly with the chemotherapy drugs causing secondary latimias, but the Genetics play a role here too.

You do?

A tragic but common clinical example from the text involves a young child who successfully survives familial retinoblastoma.

We save their life and perhaps preserve their vision, but they still possess that underlying germline mutation in the RB1 tumor suppressor gene.

That underlying risk doesn't go away.

Exactly.

When you combine that baseline genetic vulnerability with the DNA damaging effects of the radiation used to cure their eye tumor, they have a massive lifelong risk of developing osteosarcoma, a bone cancer, as a secondary malignancy when they reach adolescence.

This profound reality is where your nursing role beautifully evolves from acute bedside care to lifelong symptom management,

palliative care when necessary, and incredibly diligent proactive surveillance.

You really have to keep an eye on them.

Yes.

It also underscores the absolute necessity of genetic counseling.

For families dealing with transmissible inherited conditions like Li -Fromany syndrome, Fanconi anemia, or familial retinoblastoma, recognizing the syndrome and aggressively referring the family to specialized genetic services is a critical, irreplaceable nursing responsibility.

You're treating the whole family, essentially.

You are not just caring for the child in front of you, you are helping the family manage the profound risks for their current extended family and their future children.

As we finally wrap up this intensive tutoring session, the text introduces one final, incredibly profound concept regarding the late effects of cancer treatment at the absolute microscopic level.

It involves telomeres.

Yes.

This is a concept that truly bridges the gap between molecular biology and clinical longevity.

Let's break that down.

Telomeres are the protective, repetitive DNA caps at the ends of all our chromosomes.

Think of them like the plastic tips on the ends of shoelaces that stop the lace from fraying.

Naturally, every time a normal human cell divides, those telomeres get slightly shorter.

It's like a countdown clock.

It is the biological clock of the cell.

When the telomeres become too short, the cell can no longer divide and it ages and dies.

So what does cancer treatment do to them?

Well, aggressive cancer therapies, the radiation and the chemotherapy we use to cure these children,

inflict such immense catastrophic stress on the body's healthy cells that they induce premature, rapid telomere shortening.

Wow.

So it artificially ages the cells.

Exactly.

It forces us as clinicians and researchers to ask a deeply provocative, unsettling question.

When we utilize highly toxic, aggressively stressful treatments to save a young child's life today, are we inadvertently accelerating their cellular aging process?

That is a heavy question.

By saving their life now, are we fundamentally altering their genetic lifespan in the future?

Do the treatments that cure pediatric cancer speed up the biological clock of the survivor?

This question regarding telomere shortening and cellular aging represents the very next great frontier in oncological nursing research, and it is a biological reality your future patients will be actively navigating.

That is a heavy but incredibly fascinating and important thought to leave you with as you continue to study this material.

We have completely unpacked this chapter.

We explored the paradox of survival rates, the embryonic mesodermal origins that make pediatric cancer so unique, the incredibly complex genetic glitches and syndromes, the specific environmental risks like prenatal exposures and CT scans, and the lifelong systemic realities of survivorship.

You are well beyond rote memorization now.

You understand the foundational pathophysiology, and you are ready to tackle this material on your exams and in your clinical practice.

On behalf of the Last Minute Lecture Team, thank you so much for joining us for this deep dive, and good luck with your studies.